Results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy.
Astellas Pharma Inc. and Seagen Inc. today announced results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab) versus chemotherapy. The combination improved overall survival (OS) and progression-free survival…